Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin-binding Rho-activating protein (ABRA), also known as Striated muscle activator of Rho signaling (STARS), is a conserved actin-binding protein highly enriched in cardiac, skeletal, and smooth muscle. ABRA localizes to the sarcomere, binding actin at the Z-disc and M-line, and regulates actin polymerization through interactions with actin-binding LIM (ABLIM) proteins. By promoting the conversion of G-actin to F-actin, ABRA removes G-actin-mediated inhibition of transcriptional co-activators (such as MRTFA), which allows these modulators to activate serum response factor (SRF)-dependent gene expression, thereby influencing muscle cell proliferation, differentiation, and response to mechanical and stress stimuli[1][3][4]. ABRA is downregulated in pathological states such as dilated cardiomyopathy and upregulated in muscle hypertrophy, playing a critical role in sarcomere integrity and as a modulator in muscle physiology and disease. Although it participates in key muscle signaling pathways, it is not currently considered a primary therapeutic target or receptor and no drugs are known to directly target ABRA[4][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin-binding Rho-activating protein (ABRA).